Stifel analyst Dae Gon Ha raised the firm’s price target on Soleno Therapeutics to $74 from $59 and keeps a Buy rating on the shares. Diazoxide choline controlled-release, or DCCR, approval is the main focus today, but thereafter, commercial value hinges on the strength of its market exclusivity, the analyst tells investors. Key opinion leader input to determine the Orange Book list-ability for DCCR-related patents, if approved, leads the firm to think exclusivity – ODE, mandatory stay, and/or IP expiration – is in “good shape until mid-2030s,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics initiated with a Buy at H.C. Wainwright
- Largest borrow rate increases among liquid names
- Soleno announces FDA acceptance for filing, priority review of NDA for DCCR
- Soleno Therapeutics Announces Board Reshuffle and New Appointments
- Soleno appoints Bir to board of directors, Chairman Mario stepping down